182 related articles for article (PubMed ID: 1448183)
1. Lidocaine has a narrow antiarrhythmic dose range against ventricular arrhythmias induced by programmed electrical stimulation in conscious postinfarction dogs.
Krejcy K; Krumpl G; Todt H; Raberger G
Naunyn Schmiedebergs Arch Pharmacol; 1992 Aug; 346(2):213-8. PubMed ID: 1448183
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of antiarrhythmic efficacy of propafenone as assessed by programmed electrical stimulation in conscious dogs.
Todt H; Krumpl G; Krejcy K; Raberger G
J Cardiovasc Pharmacol; 1992 Mar; 19(3):341-8. PubMed ID: 1378111
[TBL] [Abstract][Full Text] [Related]
3. Failure of lidocaine to suppress lethal ischemic ventricular arrhythmias in a canine model of previous myocardial infarction.
Lynch JJ; Heaney LA; Wallace AA; Gehret JR; Stein RB
J Cardiovasc Pharmacol; 1990 Jul; 16(1):41-9. PubMed ID: 1696665
[TBL] [Abstract][Full Text] [Related]
4. Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: a comparative study with dobutamine.
Ozaki T; Uematsu T; Nagashima S; Nishimoto M; Nakashima M
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):478-87. PubMed ID: 1766473
[TBL] [Abstract][Full Text] [Related]
5. Programmed electrical stimulation after myocardial infarction and reperfusion in conscious dogs.
Krumpl G; Todt H; Schunder-Tatzber S; Raberger G
J Pharmacol Methods; 1990 Apr; 23(2):155-69. PubMed ID: 2332981
[TBL] [Abstract][Full Text] [Related]
6. Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction.
Hashimoto H; Satoh N; Nakashima M
J Cardiovasc Pharmacol; 1992 Mar; 19(3):417-24. PubMed ID: 1378123
[TBL] [Abstract][Full Text] [Related]
7. Effect of ajmaline on sustained ventricular tachycardia induced by programmed electrical stimulation in conscious dogs after myocardial infarction.
Todt H; Krumpl G; Zojer N; Krejcy K; Raberger G
Naunyn Schmiedebergs Arch Pharmacol; 1993 Sep; 348(3):290-7. PubMed ID: 7694159
[TBL] [Abstract][Full Text] [Related]
8. The effect of intracoronary lidocaine on ventricular arrhythmia in the infarcted canine heart.
Tordjman T; Raeder E; Lampert S; Lown B
Pharmacotherapy; 1988; 8(5):295-8. PubMed ID: 3252195
[TBL] [Abstract][Full Text] [Related]
9. Facilitation of reentry by lidocaine in canine myocardial infarction.
Fazekas T; Scherlag BJ; Mabo P; Patterson E; Lazzara R
Acta Physiol Hung; 1994; 82(3):201-13. PubMed ID: 7717083
[TBL] [Abstract][Full Text] [Related]
10. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
Black SC; Butterfield JL; Lucchesi BR
J Cardiovasc Pharmacol; 1993 Dec; 22(6):810-8. PubMed ID: 7509898
[TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic and arrhythmogenic actions of methyl lidocaine during the recovery phase after canine myocardial infarction.
Patterson E; Gibson JK; Lucchesi BR
Pharmacology; 1988; 36(2):73-83. PubMed ID: 3353442
[TBL] [Abstract][Full Text] [Related]
12. Antiarrhythmic actions of tocainide in canine models of previous myocardial infarction.
Wallace AA; Stupienski RF; Heaney LA; Gehret JR; Lynch JJ
Am Heart J; 1991 May; 121(5):1413-21. PubMed ID: 1708198
[TBL] [Abstract][Full Text] [Related]
13. The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterobicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heart.
Fazekas T; Scherlag BJ; Mabo P; Berlin KD; Garrison GL; Chen CL; Sangiah S; Patterson E; Lazzara R
Acta Physiol Hung; 1993; 81(3):289-99. PubMed ID: 8197884
[TBL] [Abstract][Full Text] [Related]
14. Lidocaine converts inducible ventricular fibrillation into sustained ventricular tachycardia in conscious dogs with recent myocardial infarction.
Aidonidis I; Brachmann J; Rizos I; Toutouzas P; Kübler W
Cardiology; 1994; 85(6):378-87. PubMed ID: 7697673
[TBL] [Abstract][Full Text] [Related]
15. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model.
Kondoh K; Hashimoto H; Nishiyama H; Umemura K; Ozaki T; Uematsu T; Nakashima M
J Cardiovasc Pharmacol; 1994 Apr; 23(4):674-80. PubMed ID: 7516022
[TBL] [Abstract][Full Text] [Related]
16. Dose-Dependent Effects of Ranolazine on Reentrant Ventricular Arrhythmias Induced After Subacute Myocardial Infarction in Rabbits.
Moschovidis V; Simopoulos V; Stravela S; Dipla K; Hatziefthimiou A; Stamatiou R; Aidonidis I
J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):65-71. PubMed ID: 31242756
[TBL] [Abstract][Full Text] [Related]
17. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
Drexler AP; Micklas JM; Brooks RR
J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
[TBL] [Abstract][Full Text] [Related]
18. Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction.
Lynch JJ; DiCarlo LA; Montgomery DG; Lucchesi BR
Pharmacology; 1987; 35(4):181-93. PubMed ID: 3118399
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of proarrhythmic activity with the class IC antiarrhythmic agent encainide in a canine model of previous myocardial infarction.
Wallace AA; Stupienski RF; Kothstein T; Gehret JR; Lynch JJ
J Cardiovasc Pharmacol; 1993 Mar; 21(3):397-404. PubMed ID: 7681500
[TBL] [Abstract][Full Text] [Related]
20. Antiarrhythmic effects of desethylamiodarone in dogs with subacute myocardial infarction and inducible ventricular arrhythmias.
Abdollah H; Brien JF; Brennan FJ
J Cardiovasc Pharmacol; 1989 Jan; 13(1):37-44. PubMed ID: 2468934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
